Join the club for FREE to access the whole archive and other member benefits.

Longevity Leaders' latest report on how longevity is disrupting the world

An interesting collection of interviews and white-papers with industry leaders

01-Jan-2020

Key points from article :

Report looks at disrupting influence of longevity across markets.

Buck Institute is focussed on genes that affect healthspan and lifespan.

It's CEO, Eric Verdin, explains why biomarkers are critical to ageing research.

Joan Mannick (resTORbio) and Steven Braithwaite (Alkahest) discuss other challenges.

Early human trials will help to improve trial designs.

We see increased heterogeneity as patients get older.

Easier to demonstrate that a therapeutic can treat rather than prevent a disease.

Angela Tyrell (Longevity Leaders SVP) looks at trends in the wellgevity market.

Includes digital tracking, consumer testing, diet and mental health.

Jackie Marshall Cyrus talks about wellbeing in later life.

Healthcare professionals often ignore the sexuality of adults past a completely subjective age range.

Mentioned in this article:

Click on resource name for more details.

Alkahest

Biotechnology company focused on treating neurodegenerative and other age-related diseases

Angela Tyrrell

Senior Vice President at Longevity Leaders & LSX and Founder and SVP at Female Founders

Buck Institute

Independent biomedical research institute focused on aging

Eric Verdin

CEO & President at Buck Institute for Research on Aging

Jackie Marshall Cyrus

Visiting Lecturer and Module Leader at Birmingham City University and Founder and Director of Jackie’s Revolution CIC

Joan Mannick

Co-Founder and CEO at Tornado Therapeutics

resTORbio

Biopharmaceutical company developing therapeutics for aging-related diseases.

Steven Braithwaite

CSO at Alkahest, Inc.

Topics mentioned on this page:
Investments, Ageing Research